Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
32 Cards in this Set
- Front
- Back
|
Atorvastatin *Class *MOA *Use *Adverse Effects *CI |
HMG-CoA reductase inhibitors (Statins) MOA: HMG-CoA is the rate limiting enzyme in cholesterol synthesis Use: High cholesterol Adverse: LFT Elevation, CPK elevation, Rhabdomyolysis, myopathy CI: Pregnancy *Statins accumulate when combine with CPY inhibitors (cyclosporine, ketoconazole, fibrates, lipopeptides) -->Rhabdomyolysis *Statins excreted with CPY inducers (Phenytoin, Rifampin) |
|
|
Niacin *Class *MOA *Use *Adverse Effects *CI |
Niacin MOA: Increases HDL. Inhibits lipolysis of TG in adipose tissue = drop in FFA Use: High cholesterol Adverse: Cutaneous flush, hepatotoxicity CI: Hepatic disease, Active PUD, caution in DM |
|
|
Gemfibrozil *Class *MOA *Use *Adverse Effects *CI |
Fibric Acid Derivatives (Fibrates) MOA: PPAR-Alpa agonist --> Increase LPL, Increase HDL, Decrease TG Use: High Cholesterol Adverse: Lithiasis, Myopathy, Myositis CI: Pregnancy, hepatic or renal dysfunction |
|
|
Cholestyramine *Class *MOA *Use *Adverse Effects *CI |
Bile Acid Sequestrants (resins) MOA: Binds up bile acids so fat is not absorbed in the gut. Use: High cholesterol Adverse: constipation, nausea, impaired ADEK absorption CI: diverticulitis, bowl disease, cholestasis *Impairs absorption of other drugs
|
|
|
Ezetimibe *Class *MOA *Use *Adverse Effects *CI |
Cholesterol Absorption inhibitor MOA: inhibits absorption of cholesterol Use: Adverse: diarrhea CI: Taking BA sequestrants |
|
|
Lomitapide *Class *MOA *Use *Adverse Effects *CI |
Familial Hypercholersterolemia MOA: Oral dose, inhibits apoB synthesis, inhibits TG transfer protein. Use: Homozygous Familial Hypercholesterolemia Adverse: diarrhea, nausea, liver transaminase elevation, hepatic fat accumulation. CI: Pregnancy |
|
|
Mipomersen *Class *MOA *Use *Adverse Effects *CI
|
Familial Hypercholersterolemia MOA: weekly injection inhibits apo B100 synthesis, causing a decrease in LDL and VLDL Use: Homozygous Familial Hypercholesterolemia Adverse: HA, Liver transaminase elevation, pain or redness @ injection site, flue-like symptoms. CI: hepatic impairment or liver disease |
|
|
Fenofibrate *Class |
Fibric Acid Derivatives (Fibrates) |
|
|
Colesevelam *Class |
Bile Acid Sequestrants (resins) |
|
|
Colestipol *Class |
Bile Acid Sequestrants (resins) |
|
|
Warfarin *Class *MOA *Use *CI
|
Anti-coagulent MOA: inhibits vit K-dependent mod of clotting factors (Thrombin, VII, IX, X) Use: DVT, PE, A Fib, Rheumatic Heart Disease. Mechanical Heart valves, Dialated cardiomyopathy. CI: Hemorrhage, pregnant, severe hypertension, anorexia, nausea, vomiting, diarrhea *Monitor with PT time adjusted to INR |
|
|
Heparin (UFH) *Class *MOA *Use *CI
|
Anti-coagulent MOA: binds to anti-thrombin III and inactivates clotting factors in the common and intrinsic pathways (Thrombin, IXa, Xa, XIa, XIIa) prolongs the aPTT and thrombin time. @ high doses PT also. Use: MI, unstable angina, DVT, PE, DIC, TIA CI: Active bleeding or hemorrhage, HTN, Recent surgery, TB, GI ulcer *overlapped with warfarin therapy in long term anti-coagulant therapy *HIT Syndrome possible complication *Monitored by aPTT (x1.5-2 normal) *Protamine Sulfate antidote for overdose |
|
|
Fondaparinux *Class *MOA *Use *Adverse Effects *CI |
Anti-coagulent MOA: Use: Adverse: CI: |
|
|
Dabigatran *Class *MOA *Use *CI |
Anti-coagulent MOA: Binds Thrombin, both clot bound and circulating. Reduces thrombin-induced platelet aggregation. Use: CI: *Requires nt monitor via INR "Non-inferior to warfarin in efficacy and safety" |
|
|
Rivaroxaban, Apixaban *Class *MOA *Use *Adverse Effects *CI |
Anti-coagulent MOA: Direct factor Xa inhibitors Use: Adverse: CI: *Requires no monitor via INR *Way more expensive than Warfarin *Rapid onset (no need for UFH Tx) *Less DDI than Warfarin "Non-inferior to warfarin in efficacy and safety" |
|
|
Enoxaprin *Class *MOA *Use *Adverse Effects *CI |
Anti-coagulent (LMWH) MOA: Greated anti-Xa, less anti-platelet, Use: SQ injection for prophylaxis of DVT *No aPTT monitoring required *Less protein binding *No endothelial cell binding *No dose dependent clearance *Longer Lasting |
|
|
Dalteprin *Class |
Anti-coagulent (LMWH)
|
|
|
Tinzaprin *Class |
Anti-coagulent (LMWH) |
|
|
Lepirudin, Bivalirudin, Argatroban *Class *MOA *Use *CI |
Direct Thrombin Inhibitors MOA: Bind directly to thrombin with high selectivity Use: Pts with HIT Syndrome CI:
|
|
|
Aspirin *Class *MOA *Use *Adverse Effects *CI |
Anti-Platelet Drugs MOA: Inhibits COX-1 and COX-2 @ very low doses. @ higher doses inhibits Prostacycin (PGI2) Use: Prophylaxis of MI, Post-MI, prevent CVD, reductions in complications with heart valves.
|
|
|
Clopidogrel *Class *MOA *Use *Adverse Effects *CI |
Anti-Platelet Drugs MOA: Irreveribly inhibits P2Y 12 Gi receptor --> decrease in platelet agg. Use: prophylaxis of MI, stroke, PAD, ACS |
|
|
Dipyridamole *Class *MOA *Use *Adverse Effects
|
Anti-Platelet Drugs MOA: platelt aggregation inhibitor Use: prevention of MI and stroke Adverse: HA
|
|
|
Abciximab *Class *MOA
|
Anti-Platelet Drugs MOA: monoclonal antibody prevents fibrinogen binding to GP IIb-IIIa
|
|
|
Prasugrel *Class *MOA |
Anti-Platelet Drugs MOA: Irreveribly inhibits P2Y 12 Gi receptor --> decrease in platelet agg. |
|
|
Cilostazole *Class *MOA *Use *CI |
Anti-Platelet Drugs MOA: Inhibits PDE III causing increase in cAMP -->PKA --> decreased platelet aggregation and increased vasodialation Use: pt with PAD clodication CI: CHF |
|
|
Pentoxifylline *Class *MOA *Use *CI |
Anti-Platelet Drugs MOA: Competative non-selective Inhib Phosphodiestarase causing increase in cAMP -->PKA --> decreased platelet aggregation and stimulates vasodialation Use: pt with PAD clodication CI: CHF |
|
|
Eptifibatide *Class |
Anti-Platelet Drugs |
|
|
Tirofiban *Class |
Anti-Platelet Drugs |
|
|
Alteplase *Class *MOA |
Thrombolytic Drugs MOA: activates tPA to cause fibrinolysis Adverse: Serious Hemorrhage |
|
|
Reteplase *Class |
Thrombolytic Drugs MOA: activates tPA to cause fibrinolysis, but diffuses into the clot more actively than alteplase. Also has shorter half life. |
|
|
Tenecteplase *Class *MOA *Use |
Thrombolytic Drugs MOA: Use: drug of choice for fibrinolytics *easier to administer *Less bleeding than the other two drugs |
|
|
Streptokinase *Class *MOA *Adverse |
Thrombolytic Drugs MOA: plasminogen activator Adverse: Serious Hemorrhage |
